Where does Pro Cell Therapies, LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Pro Cell Therapies, LLC ranks #37,069 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Pro Cell Therapies, LLC hold?

Pro Cell Therapies, LLC holds 7 US utility patents granted between 2017 and 2024, spanning 1 technology areas.

What is Pro Cell Therapies, LLC's Innovation Score?

Pro Cell Therapies, LLC has an Innovation Score of 25.3 out of 100 (17th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Pro Cell Therapies, LLC's patent grant rate increasing or decreasing?

Pro Cell Therapies, LLC's recent grant velocity is +500% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Pro Cell Therapies, LLC's patents?

Pro Cell Therapies, LLC's patents average 2.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Pro Cell Therapies, LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Pro Cell Therapies, LLC

Q: What technology areas does Pro Cell Therapies, LLC focus on?

Pro Cell Therapies, LLC's top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 1 patents, ranking #2,627 of 3,490 assignees active in that subclass. Grants appear in 1 CPC subclasses total.

USPTO PatentsView assignee record - 7 granted patents across 1 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Pro ranks #37,069 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 1 technology areas.

#37,069
of 49,997 US assignees by volume: 17th percentile
by Innovation Score (25.3/100): 2.1
avg claims per patent: +500%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R37069 · US Corporation #37,069 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-SPARSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 7 grants
MID-PACK #37,069/49,997
PHOTO-FINISH PrimeWan
CPC-NARROW A61M · 1 areas
INNOV-THIN 25.3/100
CLAIMS-SPARSE 2.1 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +500% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: PrimeWan Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Pro’s 25.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (28%) Velocity 13.3 pts (53%) Breadth 3.5 pts (14%) Claim depth 1.3 pts (5%)

Qualcomm Incorporated · highest

85
Pro Cell Therapies · this assignee

25
3D Lighting… · lowest

7

What this shows Pro's Innovation Score is 25.3/100 (17th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Pro?

Each dot is one of Pro’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Pro’s own 2.1 claims/patent is at or below the 13.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Pro vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Pro's grants concentrate

Pro Cell Therapies, LLC is a focused PatentsView assignee: 1 CPC subclasses with 14.3% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2024 (4 grants) versus a trough of 1 in 2017. By volume, Pro sits between PrimeWan Limited and Progressive Products, Inc..

Pro's three-year grant acceleration

Pro Cell Therapies, LLC shows 4 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Primewan

7
Prince Lionheart

7
Prince Sultan Uni…

7
Priority 5 Holdin…

7
Proact Services

7
Promed

7
Progeny Advanced…

7
Progressive Produ…

7
Pro Cell Therapies ◀

7

What this shows Pro holds 7 patents at rank #37,065, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Pro

By rank, the assignees closest to #37,065 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Pro's primary technology class.

Pro's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

25 17th percentile higher than 17% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Pro Cell Therapies, LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	14.3%
2020	1	14.3%
2021	1	14.3%
2024	4	57.1%

Which technologies does Pro Cell Therapies, LLC patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

Top 1 of 1 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Pro Cell Therapies, LLC's patent record in context - here's where to go next.

Pro Cell Therapies, LLC's lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 14.3% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #37,069 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Pro Cell Therapies, LLC against PrimeWan Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 25.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.